Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the efficacy and safety of a combination budesonide and albuterol metered dose inhaler BDA MDI compared with an albuterol sulfate AS metered dose inhaler in symptomatic Chinese adults with asthma. This randomized, double-blind, Phase III study aims to reduce the risk of severe asthma exacerbations in participants who have had asthma diagnosed for at least 12 months and currently use maintenance therapies. The study involves about 1000 eligible participants randomly assigned to receive either BDA MDI 160180 mcg delivered as two actuations of 8090 mcg or AS MDI 180 mcg delivered as two actuations of 90 mcg. Both treatments are used as needed for asthma symptoms or before exercise. The trial includes a screening period lasting 14 to 28 days, followed by a treatment period of at least 24 weeks and up to 52 weeks, and concludes with a safety follow-up about two weeks after the last treatment visit. Participants will be assessed through various visits during the study, including evaluations of lung function, asthma control questionnaires ACQ-5 and ACQ-7, and monitoring of severe asthma exacerbations. The primary outcome is the time to the first severe asthma exacerbation over the treatment period. Secondary outcomes include the rate of exacerbations, steroid exposure, and patient-reported measures of asthma control and quality of life. Safety and adherence are closely monitored throughout the study duration.
Actively Recruiting
Researchers are conducting a large observational study called the China HeadAche Disorders Registry CHAIRS to better understand primary headaches and medication-overuse headaches MOH in patients aged 12 years and older. The study aims to collect detailed information including biomarkers, brain imaging, cognitive and genetic data, as well as social, demographic, medical, and treatment-related data. Long-term follow-up is planned to observe outcomes related to headache disorders over many years. Participants include those with various types of primary headaches such as migraine, tension-type headache, new daily persistent headache, and MOH. The study includes behavioral follow-up visits at multiple time points monthly for the first 18 months, then at 24 months, and annually thereafter. Some participants are observed during routine clinical use of treatments like Yangxue Qingnao Granules, Erenumab, and Eptinezumab, with treatment decisions made by their physicians and outcomes tracked over 12 weeks or longer. Throughout the study, participants undergo periodic assessments including MRI scans, cognitive tests like the Montreal Cognitive Assessment MoCA and Mini-Mental State Exam MMSE, and questionnaires evaluating headache impact, anxiety, depression, quality of life, sleep quality, and fatigue. Data on headache frequency, severity, medication use, and biological samples are collected. Follow-up can extend up to 10 years, allowing researchers to monitor long-term changes and outcomes related to headache disorders and treatments.